Next Article in Journal
Open-Ended Coaxial Probe Technique for Dielectric Measurement of Biological Tissues: Challenges and Common Practices
Next Article in Special Issue
A Novel Technique for Intraoral Ultrasound-Guided Aspiration of Peritonsillar Abscess
Previous Article in Journal
Comment on Thigpen D. et al. The Role of Ultrasound in Screening Dense Breasts—A Review of the Literature and Practical Solutions for Implementation. Diagnostics 2018, 8, 20
Previous Article in Special Issue
Improving Remote Health Monitoring: A Low-Complexity ECG Compression Approach
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(2), 39; https://doi.org/10.3390/diagnostics8020039

Developments in Point-of-Care Diagnostic Technology for Cancer Detection

1
Translational Health Sciences, Bristol Medical School, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK
2
School of Biotechnology, Dublin City University, Collins Avenue, Glasnevin, Dublin D09 Y5N0, Ireland
3
Hamad Bin Khalifa University, Research Complex, P.O. Box 34110 Doha, Qatar
*
Author to whom correspondence should be addressed.
Received: 2 May 2018 / Revised: 22 May 2018 / Accepted: 25 May 2018 / Published: 2 June 2018
(This article belongs to the Special Issue Novel Point-of-Care Technologies in Diagnostics 2018)
Full-Text   |   PDF [2189 KB, uploaded 2 June 2018]   |  

Abstract

Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths. View Full-Text
Keywords: cancer; diagnostics; point-of-care; glycosylation; circulating tumor cells; prostate cancer; biomarkers; exosomes; autoantibodies cancer; diagnostics; point-of-care; glycosylation; circulating tumor cells; prostate cancer; biomarkers; exosomes; autoantibodies
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hayes, B.; Murphy, C.; Crawley, A.; O’Kennedy, R. Developments in Point-of-Care Diagnostic Technology for Cancer Detection. Diagnostics 2018, 8, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top